Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vyne Therapeutics Inc VYNE

Healthcare
VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its... see more

Recent & Breaking News (NDAQ:VYNE)

Menlo Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire May 31, 2018

Menlo Therapeutics Reports First Quarter 2018 Financial Results

GlobeNewswire May 9, 2018

Menlo Therapeutics Announces Senior Clinical Leadership Updates

GlobeNewswire May 7, 2018

Benzinga's Biotech Pulse: Takeda Sweetens Shire Offer Again, Menlo's Woes Abound, Earnings Fail to Boost Amgen

Benzinga.com  April 25, 2018

Detailed Research: Economic Perspectives on Menlo Therapeutics, Potbelly, Maximus, Veeva, RLJ Lodging Trust, and Net Element — What Drives Growth in Today's Competitive Landscape

GlobeNewswire April 18, 2018

Mid-Day Market Update: Dow Rises 250 Points; Menlo Therapeutics Shares Slide

Benzinga.com  April 9, 2018

Mid-Morning Market Update: Markets Open Higher; Novartis To Acquire AveXis For $8.7B

Benzinga.com  April 9, 2018

Benzinga Pro's 5 Stocks To Watch Today

Benzinga.com  April 9, 2018

5 Stocks To Watch For April 9, 2018

Benzinga.com  April 9, 2018

Menlo Therapeutics Announces Results from a Phase 2 Trial of Serlopitant for Pruritus Associated with Atopic Dermatitis

GlobeNewswire April 8, 2018

Menlo Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

GlobeNewswire March 28, 2018

Menlo Therapeutics’ Phase 2 Serlopitant Study for the Treatment of Chronic Pruritus Published in the Journal of the American Academy of Dermatology

GlobeNewswire February 20, 2018

Menlo Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire January 29, 2018

Menlo Therapeutics Inc. Announces Pricing of Initial Public Offering of Common Stock

GlobeNewswire January 24, 2018